Investments in the biotech, pharmaceutical and life science sectors have seen some good returns since COVID struck. While it is true that much of the initial gains have been retraced, Dr Navid Malik, a medically trained specialist who is now a life sciences, pharma and biotech analyst, says there is more to come as the sector prepares for more vaccines to combat new variants, and also brings the illusive COVID pill to the market. 

Any opinion, news, research, analysis, or other information does not constitute investment or trading advice. 

Follow us on Twitter, Instagram and YouTube